Skip to main content
2024 Midyear Clinical Meeting & Exhibition Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
Certified Pharmacy Executive Leader
Certified Pharmacy Executive Leader
Digital Health & Informatics
Digital Health & Informatics
Diversity, Equity and Inclusion
Diversity, Equity and Inclusion
Health & Wellness
Health & Wellness
Opioids & Pain Management
Opioids & Pain Management
Sterile Compounding
Sterile Compounding
Handout Recording

Educational Sessions

Let the Debate Begin: GLP-1 Receptor Agonists vs. Newer Incretin Mimetics for Obesity and Type 2 Diabetes

Tuesday, December 10, 2024
8:00 AM - 9:15 AM  
Location: MCCNO, Ballroom C, Level 2
CE Credits: 1.25 contact hours
Activity #: 0204-0000-24-285-L01-P
Activity Type: Application-based
Target Audience: Pharmacist

Learning Objectives:

  • Summarize treatment recommendations for type 2 diabetes and obesity from the American Diabetes Association's Standards of Care in Diabetes and the American Association of Clinical Endocrinology.
  • Given a case scenario, assess the benefits, risks, and barriers of GLP-1 receptor agonists for type 2 diabetes and obesity.
  • Given a case scenario, assess the benefits, risks, and barriers of dual and triple incretin mimetics for type 2 diabetes and obesity.